Unlike the dopplegängers of folklore or the evil twins of popular entertainment, digital twins don’t just appear seemingly out of nowhere. They are painstakingly developed and refined. And neither are ...

In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...

Generative AI based on Large Language Models (LLMs), the technology behind popular tools like ChatGPT and Google Gemini, is revolutionizing various industries, including the world of drug discovery.

Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical ...

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

FDA recently issued two draft guidance documents discussing: (1) the use of artificial intelligence (AI) to produce information to support a regulatory decision about a drug or biological product’s ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...